AI is transforming drug discovery by boosting early-stage clinical trial success rates to 80%–90%, compared to the traditional 40%–65%, and contributing to nearly half of preclinical drug development output.
Leveraging big data and advanced deep learning models, AI accelerates target identification, molecular design, and clinical trial optimization, saving millions in costs and months in timelines. Notable breakthroughs include AI-designed antibodies and drug repositioning successes.
This article explores how, despite challenges such as data quality and transparency, combining AI with ethical oversight and collaboration promises faster, more precise, and patient-focused pharmaceutical innovation.
By Eratha Poongkuntran, Associate Director, Avasant
Avasant’s research and other publications are based on information from the best available sources and Avasant’s independent assessment and analysis at the time of publication. Avasant takes no responsibility and assumes no liability for any error/omission or the accuracy of information contained in its research publications. Avasant does not endorse any provider, product or service described in its RadarView™ publications or any other research publications that it makes available to its users, and does not advise users to select only those providers recognized in these publications. Avasant disclaims all warranties, expressed or implied, including any warranties of merchantability or fitness for a particular purpose. None of the graphics, descriptions, research, excerpts, samples or any other content provided in the report(s) or any of its research publications may be reprinted, reproduced, redistributed or used for any external commercial purpose without prior permission from Avasant, LLC. All rights are reserved by Avasant, LLC.
Login to get free content each month and build your personal library at Avasant.com
